



ASX ANNOUNCEMENT

VOLPARA COMPLETES ACQUISITION OF MRS SYSTEMS

Wellington, NZ, 14th June 2019: Volpara Health Technologies Limited ("**Volpara**"; ASX: VHT), a medical technology company whose AI imaging algorithms assist the early detection of breast cancer, is pleased to announce that it has completed its acquisition of Seattle-based MRS Systems, Inc. (**MRS Systems**), following Volpara's initial announcement of the proposed acquisition to the ASX on 3 June 2019.

Dr Ralph Highnam, Volpara CEO, said of the acquisition's completion: "We are delighted to welcome MRS Systems and its people into the Volpara group. And we are excited about the opportunity to work alongside MRS Systems in the United States and to grow Volpara's service offering in the increased number of US breast clinics to which Volpara now has immediate access. The acquisition has involved a tremendous effort from people in both organisations, and I would like to express my thanks to everyone as we look forward to the future with a stronger US base and an extended range of integrated products which will help detect breast cancer earlier."

MRS Systems, Inc.

MRS Systems is a medical software company that provides comprehensive patient tracking and communication, and a radiology reporting platform for sub-specialty radiology applications including breast and lung imaging.

The acquisition of MRS Systems is consistent with Volpara's goal to save families from breast cancer through the use of AI imaging algorithms to assist the early detection of breast cancer. Application of AI requires well-curated data, and the combination of the two companies opens up that potential.

The acquisition of MRS Systems instantly increases the number of US breast clinics to which Volpara has access from ~400 to over 2,000 (an increase of more than 400%). This access will provide a platform to enable many more women to benefit from Volpara's clinical and enterprise management software while ultimately generating the massive amounts of data that optimise AI.

In the shorter term, it is expected that the acquisition will provide Volpara with the following:

- a much stronger US presence; technical expertise; and a mature, experienced US headquarters based in Seattle
- a significant increase in annual recurring revenue (ARR)
- accelerated sales through cross-selling opportunities
- increased potential average revenue per user (ARPU) through new products for the sales team

Retail Entitlement Offer

The retail component of Volpara's Entitlement Offer is ongoing.

The Entitlement Offer will close at **5.00 pm (Sydney time) on Wednesday, 26 June 2019**, unless extended. Eligible retail shareholders who wish to participate in the Entitlement Offer are encouraged to complete and return their personalised entitlement and acceptance form as soon as possible by one of the methods set out in the Offer Booklet.

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES



For further information on, or if you have any questions in respect of, the Retail Entitlement Offer, you may call the Volpara Offer Information Line on 1300 737 760 (within Australia) or +61 2 9290 9600 (outside Australia) Monday to Friday from 8.30 am to 5.30 pm (Sydney time), during the offer period.

ABOUT VOLPARA HEALTH TECHNOLOGIES LIMITED (ASX: VHT)

VHT is a MedTech SaaS company founded in 2009 on research originally conducted at Oxford University. VHT's clinical applications for screening clinics provide feedback on breast density, compression, dose, and quality, while its enterprise-wide practice software management helps with productivity, compliance, reimbursement, and patient tracking.

VHT's technology and services have been used by customers and/or research projects in 38 countries and are supported by numerous patents, trademarks and regulatory clearances, including FDA clearance and CE marking. Since its listing on the ASX in April 2016, VHT has raised A\$95 million, including the current proposed fully underwritten A\$55 million. VHT is based in Wellington, New Zealand.

For more information, visit www.volparasolutions.com.

IMPORTANT NOTICES

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or in any other jurisdiction. Any shares issued to eligible retail shareholders under the Entitlement Offer have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, registration under the US Securities Act of 1933 and any applicable US state securities laws.

The Information in this announcement is of general background and does not purport to be complete. It should be read in conjunction with Volpara's other periodic and continuous disclosure announcements lodged with ASX Limited, which are available at www.asx.com.au. You are advised to read these Important Notices carefully before reading or making any other use of this announcement or any information contained in this announcement. In accepting this announcement, you agree to be bound by these terms and conditions, including any modifications to them.

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES